Eton Pharmaceuticals ^{Priced, Nasdaq: ETON}

We were formed in April 2017 as a specialty pharmaceutical company focused on developing and commercializing innovative pharmaceutical products utilizing the FDA’s 505(b)(2) regulatory pathway. Our business model is to develop proprietary innovative products that fulfill an unmet patient need. Since our formation, we have focused our efforts on the development and testing of our initial product candidates, the submission of an NDA for our initial product candidate and preliminary discussions with the FDA concerning the regulatory pathway for certain additional product candidates. Our plan of operations for the 12-month period following the completion of this offering is to obtain FDA approval of our lead candidate, DS-300, a patent-pending injectable product candidate. DS-300’s NDA was filed with the FDA in January 2018. DS-300 has been granted Fast Track Designation by the FDA and is being reviewed by the FDA as a rolling review. We currently have seven other product candidates in various stages of development. We also intend to develop our own laboratory in Lake Zurich, Illinois. Finally, our 12 month plan of operations includes the establishment of an internal sales infrastructure.